Intra-Cellular Therapies, Inc.
430 E 29th St Ste 900
New York
New York
10016
United States
Website: http://www.intracellulartherapies.com/
Email: info@intracellulartherapies.com
About Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies Inc. is a publicly traded biopharmaceutical company headquartered in New York City. Founded on Nobel-prize winning research, we launched our first commercial product in CNS in 2020 and received approval for an expanded indication in 2021. Currently celebrating our 22nd anniversary, we have a strong pipeline with projects in preclinical development stage through Phase III. We celebrate science, welcome curiosity, expect collaboration and demand integrity and respect in all we do, create and deliver.
“We deliver innovative treatments to improve the lives of individuals suffering from neuropsychiatric, neurologic and other disorders”.
226 articles about Intra-Cellular Therapies, Inc.
-
Intra-Cellular Therapies to Present Data on Lumateperone and ITI-333 at the 58th Annual Meeting of the American College of Neuropsychopharmacology
12/4/2019
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that the Company will be presenting at the 58th Annual Meeting of the American College of Neuropsychopharmacology (ACNP) to be held in Hollywood, FL, December 8-11, 2019.
-
Intra-Cellular Therapies Provides Corporate Update and Reports Third Quarter 2019 Financial Results
11/5/2019
Intra-Cellular Therapies, Inc., a biopharmaceutical company focused on the development of therapeutics for central nervous system disorders, provided a corporate update and announced its financial results for the third quarter ended September 30, 2019.
-
Intra-Cellular Therapies to Host Third Quarter 2019 Financial Results Conference Call and Webcast
10/29/2019
Intra-Cellular Therapies, Inc. announced that it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Tuesday, November 5, 2019, to provide a corporate update and discuss details of the Company's financial results for the quarter ended September 30, 2019.
-
50 million people worldwide live with symptomatic Alzheimer's, which has no cure. In honor of September 21st being World Alzheimer's Day, we evaluated the current therapies, drugs in the pipeline and disease outlook.
-
The FDA advisory committee canceled the meeting after Intra-Cellular provided the regulatory agency with additional data. No new meeting date has been scheduled.
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intra-Cellular Therapies, Inc. - ITCI
12/18/2018
Pomerantz LLP is investigating claims on behalf of investors of Intra-Cellular Therapies, Inc. Investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.
-
Depression Awareness Month: Ketamine Clinics Put Not-Always Flattering Spotlight on Treatment
10/15/2018
Depression affects almost 20 million Americans yearly and major depressive disorders affect nearly 300 million people worldwide. The annual market for these disorders is approximately $83 billion. -
Intra-Cellular Therapies Presents Data on Lumateperone, ITI-214 and ITI-333 at the 56th Annual Meeting of the American College of Neuropsychopharmacology
12/7/2017
The meeting is being held in Palm Springs, CA, December 3-7, 2017.
-
Intra-Cellular Therapies Receives FDA Fast Track Designation for Lumateperone for the Treatment of Schizophrenia
11/20/2017
Drug candidates with Fast Track designation may also qualify for priority review to expedite the FDA review process, if relevant criteria are met.
-
Intra-Cellular Therapies Presents Data on Mechanism of Action of Lumateperone and ITI-214 at the 2017 Society for Neuroscience (SfN) Annual Meeting
11/14/2017
The event is being held in Washington DC, November 11-14.
-
Intra-Cellular Therapies Expands Its Executive Team with the Appointment of Dr. Andrew Satlin as Executive Vice President and Chief Medical Officer
11/13/2017
Dr. Satlin brings broad experience to the Company with over 20 years of industry experience in all phases of drug development in multiple therapeutic areas.
-
Intra-Cellular Therapies Reports Third Quarter 2017 Financial Results and Provides Corporate Update
11/8/2017
The company reported a net loss of $22.9 million, or $0.53 per share (basic and diluted), for the third quarter of 2017 compared to a net loss of $30.3 million.
-
Intra-Cellular Therapies to Host Third Quarter 2017 Financial Results Conference Call and Webcast
11/3/2017
To access the live conference call via phone, dial 1-(844) 835-6563.
-
Intra-Cellular Therapies Announces Full Exercise Of Underwriters’ Option To Purchase Additional Shares Of Common Stock
10/6/2017
-
Intra-Cellular Therapies Announces Commencement Of Enrollment Of A Clinical Trial Evaluating ITI-214 In Patients With Parkinson’s Disease
10/3/2017
-
Intra-Cellular Therapies Prices $150 Million Public Offering Of Common Stock
9/28/2017
-
Intra-Cellular Therapies Announces Positive Topline Data From 6-Week Open-Label Safety Switching Study With Lumateperone In Patients With Schizophrenia
9/7/2017
-
Intra-Cellular Therapies Announces Positive Regulatory Update On Schizophrenia Program
8/23/2017
-
Intra-Cellular Therapies Reports Second Quarter 2017 Financial Results And Provides Corporate Update
8/9/2017
-
Intra-Cellular Therapies Presents At The 2017 International College Of Neuro-Psychopharmacology (CINP) Thematic Meeting On Treatment-Resistant Depression
7/20/2017